biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sir_Holleron Apr 21, 2015 5:57pm

168 Views

Post# 23650397

RE:big news..........

Seems like today's announcement called for and would have been an ideal time to tell everyone what happened with the Sandhoff and Hunter Syndrome studies. I hope its not like the BT2111 survival study that was initiated and then all reference to dropped in the MD&A. The presentation on BTI's website even has the Sandhoff studies still in brain transport studies and not efficacy studies. Are they conducting the studies over again?

Bullboard Posts

How one company is disrupting PoC testing